174 related articles for article (PubMed ID: 15735923)
21. Secondary hematological malignancies associated with temozolomide in patients with glioma.
Momota H; Narita Y; Miyakita Y; Shibui S
Neuro Oncol; 2013 Oct; 15(10):1445-50. PubMed ID: 23519741
[TBL] [Abstract][Full Text] [Related]
22. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Dinnes J; Cave C; Huang S; Milne R
Br J Cancer; 2002 Feb; 86(4):501-5. PubMed ID: 11870527
[TBL] [Abstract][Full Text] [Related]
23. The evolving genomic landscape of recurrent gliomas.
Ampie L; Kusne Y; Sanai N
World Neurosurg; 2015 May; 83(5):722-3. PubMed ID: 25765925
[No Abstract] [Full Text] [Related]
24. Temozolomide in malignant gliomas: current use and future targets.
Villano JL; Seery TE; Bressler LR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Conti A; Pontoriero A; Arpa D; Siragusa C; Tomasello C; Romanelli P; Cardali S; Granata F; De Renzis C; Tomasello F
Acta Neurochir (Wien); 2012 Feb; 154(2):203-9. PubMed ID: 21984132
[TBL] [Abstract][Full Text] [Related]
27. Salvage temozolomide for prior temozolomide responders.
Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
[TBL] [Abstract][Full Text] [Related]
28. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
29. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Chamberlain MC
Expert Rev Neurother; 2010 Oct; 10(10):1537-44. PubMed ID: 20925470
[TBL] [Abstract][Full Text] [Related]
30. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Chamberlain MC
J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic astrocytoma in adults.
Stupp R; Reni M; Gatta G; Mazza E; Vecht C
Crit Rev Oncol Hematol; 2007 Jul; 63(1):72-80. PubMed ID: 17478095
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Zheludkova OG; Tarasova IS; Gorbatykh SV; Belogurova MB; Kumirova EV; Borodina ID; Prityko AG; Melikian AG; Shcherbenko OI
Vopr Onkol; 2002; 48(3):356-60. PubMed ID: 12455362
[No Abstract] [Full Text] [Related]
36. Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Kim SJ; Park TS; Lee ST; Song J; Suh B; Kim SH; Jang SJ; Lee CH; Choi JR
Ann Clin Lab Sci; 2009; 39(4):392-8. PubMed ID: 19880768
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
[TBL] [Abstract][Full Text] [Related]
38. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
39. Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Chamberlain MC; Raizer J
J Neurooncol; 2009 Jun; 93(2):229-32. PubMed ID: 19099199
[TBL] [Abstract][Full Text] [Related]
40. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Sure D; Dunn I; Norden A; Anderson WS
Clin Neurol Neurosurg; 2010 Oct; 112(8):741-2. PubMed ID: 20434832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
